Providing enabling technologies to support you from Discovery to Delivery.
› News › Application and Technology News
Oral solid dosage forms (OSDs) are one of the most prevalent drug delivery systems. Its market reached an estimate of $24.5 billion dollars back in 2016 and continually grows as the era for personalized medicine emerges.
Nutraceuticals contain nutrients derived from food products which are then formulated into different kinds of dosage forms. The definition of these drugs depends on their source - from natural resources, chemical syntheses, and pharmacological conditions.
Esco Pharma USA factory successfully completed the design, ergonomic trials, manufacture, assembly, testing, and delivery of a 14-glove double-sided R&D Laboratory Containment Isolator for one of the largest pharmaceutical manufacturing companies in the world.
High Potency Active Pharmaceutical Ingredients (HPAPIs) are drugs that represent a pivotal change in the new generation of developing patient therapies.
According to the World Health Organization (WHO), the scope of radiopharmaceutical products include organic and inorganic compounds, peptides, proteins, monoclonal antibodies and fragments, and oligonucleotides labelled with radionuclides with half-lives from a few seconds to several days.
Antibody Drug Conjugates (ADCs) are the new class of highly potent biopharmaceutical drug with high specificity for cancer therapy. The design and synthesis of an effective ADC is challenging, requiring specialized equipment for the concept to be a reality.
Variety of methods for the labeling of erythrocytes (red blood cells or RBC), leukocytes (white blood cells or WBC), and thrombocytes (platelet) have been established, employing either Tc-99m or In-111 as two of the most common radionuclides
Esco Healthcare, a member of the Esco Group of companies, is comprised of 3 divisions namely, Esco Pharma, TaPestle Rx, and Esco VacciXcell. Altogether, these 3 divisions aim to make your 2018 a year of continuous learning for unsurmountable growth and development.
